Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Diem T. Chu"'
Autor:
Roy B. Jones, Partow Kebriaei, Laura L. Worth, Amin M. Alousi, Charles Martinez, Simrit Parmar, Timothy Madden, Alan L. Myers, Elizabeth J. Shpall, J. Chen, Jitesh D. Kawedia, Diem T. Chu, Denái R. Milton, Ben C. Valdez, Marcelo Fernandez-Vina, Alison M. Gulbis, Q H Meng, Borje S. Andersson, Gheath Alatrash, Richard E. Champlin, Peter F. Thall, Uday R. Popat, Gabriella Rondon, Yago Nieto, M. de Lima
Publikováno v:
Bone marrow transplantation
We hypothesized that IV Busulfan (Bu) dosing could be safely intensified through pharmacokinetic (PK-) dose guidance to minimize the inter-patient variability in systemic exposure (SE) associated with body-sized dosing, and this should improve outcom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acbdc1320f1f2c82e6d9892bed0bf36c
http://europepmc.org/articles/PMC5382042
http://europepmc.org/articles/PMC5382042
Autor:
Chitra Hosing, Partow Kebriaei, Laura L. Worth, Borje S. Andersson, Roy B. Jones, Peter F. Thall, Amin M. Alousi, Elizabeth J. Shpall, Diem T. Chu, Gabriela Rondon, Richard E. Champlin, Patricia S. Fox, Uday R. Popat, Ben C. Valdez
Publikováno v:
Biology of Blood and Marrow Transplantation. 20(2):S152-S153
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3bb36e3b2bd3375b7fef677faabf1dc
Autor:
Borje S. Andersson, Peter F. Thall, Joshua Howell, M. de Lima, Diem T. Chu, Stefan O. Ciurea, P. Matteo, Richard E. Champlin, Alison M. Gulbis
Publikováno v:
Biology of Blood and Marrow Transplantation. 16(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4c9000d65d347391135c6fbafc9f40a
Autor:
Simrit Parmar, Partow Kebriaei, Issa F. Khouri, Amin M. Alousi, Susanna R Campos, Richard E. Champlin, J. Chen, Sairah Ahmed, Uday R. Popat, Gabriela Rondon, Marcos de Lima, Chitra Hosing, Elizabeth J. Shpall, Diem T. Chu, Glenda Woodworth, Alexandre Chiattone, Jorge E. Cortes, Jean Pierre J. Issa
Publikováno v:
Blood. 118:3106-3106
Abstract 3106 Background Allogeneic stem cell transplantation (SCT) is potentially curative for patients with CML who fail tyrosine kinase inhibitor (TKIs) treatment but remain in chronic phase (CP). In addition, TKI may ‘downstage’ advanced dise
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa6855151e2634212a6395bec4373866
https://doi.org/10.1182/blood.v118.21.3106.3106
https://doi.org/10.1182/blood.v118.21.3106.3106
Autor:
Paolo Anderlini, Elizabeth J. Shpall, Gaurav Parik, Muzaffar H. Qazilbash, S. Qureshi, Richard E. Champlin, Partow Kebriaei, Chitra Hosing, Wamique S. Yusuf, Uday R. Popat, Diem T. Chu, Farhan J. Bukhari, Rima M. Saliba, Sergio Giralt, Marcos DeLima, Amin M. Alousi, Issa F. Khouri
Publikováno v:
Blood. 110:3002-3002
BACKGROUND: Both autologous and allogeneic stem cell transplantation (SCT) are potentially curative treatment options for patients with hematologic malignancies. Due to a high risk of regimen-related toxicity, only patients with satisfactory organ-sy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d340b87c7963c43e73016eee4eca54ea
https://doi.org/10.1182/blood.v110.11.3002.3002
https://doi.org/10.1182/blood.v110.11.3002.3002
Autor:
Chitra Hosing, Issa F. Khouri, Diem T. Chu, D. L. Bethancourt, Sergio Giralt, M. Donato, Richard E. Champlin, Sandra Acholonu, M. Duvic
Publikováno v:
Journal of Clinical Oncology. 24:7540-7540
7540 Background: Patients (pts.) with advanced CTCL have a poor prognosis. There has been limited experience with the use of allogeneic hematopoietic stem cell transplantation (HSCT) in these pts. We report the results of 11 pts. with advanced CTCL/S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aaca2a688951512bf47277f26f8544e5
https://doi.org/10.1200/jco.2006.24.18_suppl.7540
https://doi.org/10.1200/jco.2006.24.18_suppl.7540